Co-administration of berberine/gypenosides/bifendate ameliorates metabolic disturbance but not memory impairment in type 2 diabetic mice

Heliyon. 2021 Jan 22;7(1):e06004. doi: 10.1016/j.heliyon.2021.e06004. eCollection 2021 Jan.

Abstract

Cognitive impairment is a well-known complication of Type 2 diabetes mellitus (T2DM) characterized by cellular insulin resistance, chronic inflammation, and metabolic disturbances. Berberine, gypenosides and bifendate are traditional Chinese herbal medicines with multiple pharmacological activities including anti-inflammation, anti-oxidant, metabolism improvement and memory improvement. To investigate whether they have synergistic effect on T2DM metabolic syndrome and associated memory impairment, we measured in this study the effect of a low dose of berberine/gypenosides/bifendate (BGB) co-administration on metabolism and memory performance of T2DM model mice. We found that BGB co-administration ameliorated metabolic abnormalities of both high-fat diet/streptozotocin (STZ)-induced T2DM mice and db/db mice. However, it did not alleviate memory impairment in either type of T2DM model mice. Since neither berberine, gypenosides nor bifendate alone at the low dose is effective, we presume that BGB co-administration has synergistic action on T2DM metabolic syndrome. In addition, our findings suggest that higher doses of BGB might be required to ameliorate memory impairment than metabolic disturbance associated with T2DM.

Keywords: Berberine; Bifendate; Gypenosides; Memory impairment; Metabolic disturbance; Type 2 diabetes mellitus.